Use of Cyrus Bench cited in review article of human diseases caused by formin INF2 mutations
SEATTLE, WA July 13, 2020 — Cyrus Bench®, Cyrus Biotechnology, Inc.’s SaaS platform for protein engineering, has been used in a recent review article in Cellular and Molecular Life Sciences to correlate computationally predicted alterations in protein stability due to mutation with disease severity (Labat-de-Hoz L, et al. Cell Mol Life Sci. 2020).
The formin INF2 protein has emerged as an important target of mutations responsible for the appearance of focal segmental glomerulosclerosis (FSGS), which often leads to end-stage renal disease (ESRD), and for the concurrence of FSGS with Charcot–Marie–Tooth disease (CMT), a degenerative neurological disorder affecting peripheral nerves.
As part of a systematic and comprehensive analysis of the pathogenic INF2 missense mutations in patients, Cyrus Bench® ΔΔG was used to predict the impact on protein stability and structure of 54 mutations relative to the structure of the wild-type protein.
The mutations causing FSGS + CMT were generally predicted to have a more destabilizing effect than those producing only FSGS. This is consistent with the fact that FSGS + CMT mutations are more harmful than those producing isolated FSGS, because they produce earlier ESRD.
About Cyrus Biotechnology
Cyrus Biotechnology, Inc. is a privately-held Seattle-based biotechnology software company offering software and partnerships for protein engineering to accelerate discovery of biologics and small molecules for the Biotechnology, Pharmaceutical, Chemical, Consumer Products and Synthetic Biology industries. Cyrus methods are based on the Rosetta software from Prof. David Baker’s laboratory at the University of Washington and HHMI, the most powerful protein engineering software available. Cyrus customers include 13 of the top 20 Global Pharmaceutical firms and is financed by leading investors in both Technology and Biotechnology, including Trinity Ventures, Orbimed, Springrock Ventures, Alexandria Venture Investments, and W Fund.
Contacts
Cyrus Biotechnology, Inc.
Lucas Nivon, 206-258-6561
lucas@cyrusbio.com